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Objectives: Invasive mould infections are associated with a high mortality rate and the emergence of MDR
moulds is of particular concern. Calcineurin and its chaperone, the heat shock protein 90 (Hsp90), represent
an important pathway for fungal virulence that can be targeted at different levels. We investigated the antifungal
activity of compounds directly or indirectly targeting the Hsp90-calcineurin axis against different mould species.
Methods: The in vitro antifungal activity of the anticalcineurin drug FK506 (tacrolimus), the Hsp90 inhibitor
geldanamycin, the lysine deacetylase inhibitor trichostatin A and the Hsp70 inhibitor pifithrin-m was assessed
by the standard broth dilution method against 62 clinical isolates of Aspergillus spp. and non-Aspergillusmoulds
(Mucoromycotina, Fusarium spp., Scedosporium spp., Purpureocillium/Paecilomyces spp. and Scopulariopsis spp.)
Results: FK506 had variable antifungal activity against different Aspergillus spp. and was particularly active
against Mucor spp. Geldanamycin had moderate antifungal activity against Fusarium spp. and Paecilomyces
variotii. Importantly, trichostatin A had good activity against the triazole-resistant Aspergillus ustus and the
amphotericin B-resistant Aspergillus terreus as well as the MDR Scedosporium prolificans. Moreover, trichostatin
A exhibited synergistic interactions with caspofungin against A. ustus and with geldanamycin against Rhizopus
spp. for which none of the other agents showed activity. Pifithrin-m exhibited little antifungal activity.
Conclusions: Targeting the Hsp90-calcineurin axis at different levels resulted in distinct patterns of susceptibility
among different fungal species. Lysine deacetylase inhibition may represent a promising novel antifungal
strategy against emerging resistant moulds.
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Introduction
Invasive fungal infections (IFIs) are associated with a highmortality
rate in patients with haematological malignancies and solid organ
transplant recipients.1,2 Among filamentous fungi, Aspergillus
fumigatus is the most frequent cause of IFI, followed by other
Aspergillus spp. However, as the spectrum of immunosuppressed
patients is increasing, other moulds have emerged as opportunistic
pathogens.3 Mucoromycotina and Fusarium spp. account for 5%–
10%of IFI cases and are associated with a particularly highmortal-
ity rate.1,2 Scedosporium spp., Paecilomyces spp. and Scopulariopsis
spp. are nowwell-recognized causes of IFI.4–6Many of these fungal
species are less susceptible to conventional antifungal drugs and
some species (e.g. Scedosporium prolificans and Scopulariopsis
spp.) are resistant to multiple current antifungal classes. Among
Aspergillus spp., Aspergillus terreus is intrinsically resistant to
amphotericin B, while Aspergillus ustus is resistant to triazoles and
was associated with breakthrough IFI in patients receiving antifun-
gal prophylaxis.7 Alternatives to azole therapy are limited by their
toxicity (polyenes) or lack of fungicidal activity (echinocandins).
There is an urgent need for novel antifungal drug classes against
these recalcitrant moulds.
Heat shock protein 90 (Hsp90) is essential for fungal survival
and controls the activity of its client protein calcineurin in stress
responses and cell wall repair mechanisms.8,9 Another molecular
chaperone, Hsp70, is involved in the transfer of client proteins to
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Hsp90 for their subsequent activation via the Hsp90 chaperone
cycle.10
We have previously shown that targeting the Hsp90-calcineurin
pathway may represent a novel antifungal strategy.9 FK506
(tacrolimus) is a calcineurin inhibitor commonly used as immuno-
suppressive therapy. The Hsp90 inhibitor geldanamycin and its
derivatives 17-(allylamino)-17-demethoxygeldanamycin (17-AAG)
and 17-dimethylaminoethylamino-17-demethoxygeldanamycin
(17-DMAG) are being studied for anticancer therapy.11 Inhibitors
of the histone deacetylases (also referred to as lysine deacety-
lases), such as trichostatin A, cripple Hsp90 function by inducing
Hsp90 acetylation.12 These compounds display some degree
of in vitro antifungal activity against A. fumigatus,12,13 but
their activity against other moulds is unknown. Pifithrin-m
(2-phenylethynesulfonamide) inhibits Hsp70 by binding to its
C-terminal portion that interacts with Hsp90.14 The antifungal
activity of pifithrin-m is unknown. In this study, we tested the
in vitro antifungal activity of these compounds against a wide
collection of clinically relevant pathogenic moulds.
Materials and methods
FK506 (Astellas Pharma US, Deerfield, IL, USA), geldanamycin (Selleck
Chemicals, Houston, TX, USA), trichostatin A (Selleck Chemicals) and
pifithrin-m (Enzo Life Sciences, Farmingdale, NY, USA) were tested
against 2 ATCC strains (A. fumigatus MYA 3626 and Paecilomyces variotii
MYA 3630) and 60 selected clinical isolates collected at Duke University
Medical Center (Durham, NC, USA) between 2009 and 2013, including
A. fumigatus (5), Aspergillus flavus (4), A. terreus (4), A. ustus (3),
Aspergillus niger (2), Aspergillus versicolor (1), Purpureocillium lilacinus (for-
merly Paecilomyces lilacinus) (5), Paecilomyces variotii (3), Scopulariopsis
spp. (4), Rhizopus spp. (5), Mucor spp. (4), Rhizomucor spp. (2),
Lichtheimia spp. (formerly Absidia spp.) (2), Cunninghamella spp. (2),
Fusarium spp. (6), Scedosporium apiospermum (4) and S. prolificans (4).
The study was approved by the Duke Hospital Institutional Review Board.
Microbroth dilution antifungal susceptibility testing was performed
according to the CLSI procedure.15 Interpretation of results was performed
after incubation at 358C for 24 h (48 h for S. apiospermum and
Scopulariopsis spp.). Based on preliminary studies in A. fumigatus,12,13
the range of concentrations tested was 0.001–0.4 mg/L for FK506 and
0.015–16 mg/L for geldanamycin, trichostatin A and pifithrin-m. Because
of the fungistatic effect of these compounds, we did not assess the MIC,
but the minimal effective concentration (MEC), defined as the concentra-
tion at which ≥50% growth inhibition was observed by macroscopic and
microscopic evaluation.15 Based on previous results reporting synergism
between these inhibitors and standard antifungals,12,13,16,17 drug interac-
tions were assessed for some drug combinations on selected strains by
chequerboard dilution and evaluated by the fractional inhibitory concen-
tration index (FICI).18
Results
Among Aspergillus spp., susceptibility to FK506 was variable
(Table 1). Most A. fumigatus and A. terreus isolates displayed
MECs of 0.025–0.05 mg/L. FK506 was particularly active against
A. niger (0.006–0.012 mg/L), reaching .90% growth inhibition
(Figure S1A, available as Supplementary data at JAC Online).
However, A. flavus isolates tended to have higher MECs (0.1–
0.2 mg/L) and no significant effect of FK506 was observed against
A. ustus or A. versicolor. Trichostatin A had little activity against
A. fumigatus and A. flavus isolates, but had better activity
against A. niger, A. terreus, A. versicolor and A. ustus (MEC 2 mg/L
for 90% of these isolates; Figure S1D). Geldanamycin had little
activity and pifithrin-m was inactive against Aspergillus spp.
FK506, geldanamycin, trichostatin A and pifithrin-m displayed
distinct and species-specific patterns of antifungal activity against




FK506 geldanamycin trichostatin A pifithrin-m
A. fumigatus (6)b 0.025 (0.025–0.4) 16 (16 to .16) 8 (8–16) .16
A. flavus (4) 0.1 (0.1–0.2) .16 .16 (8 to .16) .16
A. terreus (4) 0.025 (0.025–0.1) 8 (8–16) 2 .16
A. niger (2) 0.006–0.012 16 to .16 2 .16
A. ustus (3) .0.4 .16 2 (2–4) .16
A. versicolor (1) .0.4 .16 2 .16
Rhizopus spp. (5) .0.4 (0.1 to .0.4) .16 16 (16 to .16) .16
Mucor spp. (4) 0.025 (0.012 to .0.4) 16 (4 to .16) .16 .16
Rhizomucor spp. (2) 0.012–0.025 8 to .16 .16 .16
Lichtheimia spp. (2) 0.2 to .0.4 .16 .16 .16
Cunninghamella spp. (2) 0.05–0.2 16 to .16 8 to .16 .16
Fusarium spp. (6) .0.4 4 (2–16) .16 .16
S. apiospermum (4) 0.05 (0.05 to .0.4) .16 8 (2 to .16) 8 (8–16)
S. prolificans (4) .0.4 .16 2 (1–8) 16 (16 to .16)
P. lilacinus (5) .0.4 .16 8 (4–16) .16
P. variotii (4)b 0.025 (0.025 to .0.4) 2 (2 to .16) 2 (0.5–16) 16 (16 to .16)
Scopulariopsis spp. (4) 0.2 (0.05 to .0.4) .16 (4 to .16) 8 (2 to .16) .16 (16 to .16)
aThe MEC50 is the concentration achieving ≥50% growth inhibition in ≥50% of tested isolates.
bIncluding one ATCC strain.
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non-Aspergillusmoulds (Table 1). All these compounds had no or
very little activity against Mucoromycotina, with the exception of
FK506, which had good activity against species of Mucor and
Rhizomucor (Figure S1B). FK506 had variable activity against
P. variotii, S. apiospermum and Scopulariopsis spp. Geldanamycin
was the only compound with significant activity against Fusarium
spp. (Figure S1A) and was also active against P. variotii. Trichostatin
A was active against all four S. prolificans isolates, with an MEC
of ≤2 mg/L for three of them (Figure S1A). Trichostatin A also had
some activity against other non-Aspergillusmoulds with the excep-
tion of Mucoromycotina and Fusarium spp. Pifithrin-m had little anti-
fungal activity against non-Aspergillusmoulds.
Drug combinations were tested against selected species that
are known to be less susceptible to conventional antifungal
drugs. A synergistic effect between trichostatin A and caspofungin
was observed against A. ustus (FICI¼0.5) (Figure S1D). However,
caspofungin did not increase the effect of trichostatin A against
S. prolificans. Neither caspofungin nor amphotericin B was able
to potentiate the antifungal activity of geldanamycin against
Fusarium spp. Various combinations of the new inhibitors were
tested against Rhizopus spp. for which all single compounds
were inactive. A synergistic effect was observed between trichos-
tatin A and geldanamycin (Figure S1B). This combination did not
have any positive interaction against othermoulds including other
Mucoromycotina. While FK506 was highly active against Mucor
spp., the addition of low levels of posaconazole or voriconazole
resulted in a decreased effect of FK506 (Figure S1C).
Discussion
We assessed the in vitro antifungal activity of various compounds
targeting the Hsp90-calcineurin pathway against a large set of
clinically significant Aspergillus and non-Aspergillus moulds and
found distinct species-dependent patterns of antifungal activity.
Most Mucor and Rhizomucor spp. were highly susceptible to
FK506, while Rhizopus and Lichtheimia spp. were not. This distinct
effect of FK506 amongMucoromycotinamight be related to some
differences in the number of genes encoding calcineurin pathway
components.19 While data with regard to the type of interaction
between FK506 and triazoles against Mucor spp. remain contro-
versial,17,20we observed that the addition of voriconazole or posa-
conazole at concentrations corresponding to those achieved in
plasma with therapeutic or prophylactic dosing (0.25–1 mg/L)
decreased the antifungal activity of FK506. We hypothesize that
this negative interaction might be due to the stress response
induced by triazoles resulting in increased calcineurin expression
by the fungus. This finding would deserve further investigation as
mucormycosis is a well-known breakthrough IFI among patients
receiving azole prophylaxis. Geldanamycin had significant activity
only against Fusarium spp. and P. variotii. While Hsp90 is an essen-
tial gene, its basal level of expression may be much higher than
required for growth and survival,9 which may explain the limited
activity of geldanamycin against most fungal species. Trichostatin
A displayed variable antifungal activity and, notably, was particu-
larly active against some resistant mould species, such as the
triazole-resistant A. ustus, the amphotericin B-resistant A. terreus
and the MDR S. prolificans. As was previously reported for A.
fumigatus,12 trichostatin A exhibited synergistic interactions with
caspofungin against A. ustus. Moreover, the combination of trichos-
tatin A and geldanamycin was synergistic against Rhizopus spp.
Because Hsp90 and calcineurin are highly conserved in eukar-
yotes, fungus-specific inhibition of these targets is difficult to
achieve. FK506 has immunosuppressive effects in humans.
However, some fungus-specific key regions of calcineurin have
been recently identified in A. fumigatus and might represent
novel antifungal targets.21 Hsp90 inhibitors are considered for
anticancer therapy,11 but their antifungal effect is reached at con-
centrations that are above their toxic threshold. Trichostatin A
appears to be an interesting candidate as an alternative antifun-
gal therapy because of its good activity at relatively low concen-
trations (1–2 mg/L) against moulds that are resistant to the
first-line antifungal classes such as the azoles and polyenes and
because of its potential synergism with echinocandins against
Aspergillus spp. Trichostatin A was well tolerated in mice, but its
very short half-life constitutes a major limitation.22 However,
more stable trichostatin A analogues with increased half-lives
have been obtained in cancer research (vorinostat and panobino-
stat). Some of these compounds have been recently approved for
anticancer therapy or are under clinical investigation.23 Thus,
lysine deacetylase inhibitors, via indirect inhibition of the
Hsp90-calcineurin axis, represent a promising novel antifungal
drug class to improve the consistently poor outcomes of IFI due
to emerging MDR fungal pathogens.
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